
GI health care use still fell among patients who had already tried another IBS-C drug, per a real world ACG 2026 analysis.

Kyle Staller, MD, MPH, is a gastroenterologist and the director of the Gastrointestinal Motility Laboratory at Mass General.

GI health care use still fell among patients who had already tried another IBS-C drug, per a real world ACG 2026 analysis.

A real world analysis of 470 patients presented at ACG 2026 found median GI visits fell from 4.5 to 3.0 in the year after initiation

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.

Staller describes key takeaways from the 12 conditional recommendations made in the American Gastroenterological Association’s new gastroparesis guideline.

Staller describes unmet needs in gastroparesis and key recommendations for its diagnosis and management from the new AGA guidelines.

October 14th 2026